Comparison of cholinergic drug effects on regional brain glucose consumption in rats and humans by means of autoradiography and positron emission tomography

J. Blin, C. A. Ray, M. F. Piercey, J. J. Bartko, M Maral Mouradian, T. N. Chase

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Cholinergic mechanisms have been extensively studied in animals and have been implicated in the pathogenesis of human disorders such as Alzheimer's disease. However, few investigations have directly evaluated the validity of extrapolating the results of animal studies to humans. As a component of a continuing examination of the contribution of cholinergic deficits to the alterations in brain metabolism that occur in Alzeimer's disease, we have compared the effects of scopolamine and physostigmine on regional brain energy metabolism in both rats and humans, using a common region of interest atlas. In Alzheimer's patients and in rodents, physostigmine increased glucose metabolism in several regions (e.g. thalamus) and decreased it in others. Overall, there was a significant positive correlation for the effects of physostigmine in the nineteen brain regions etudied in both species (r = 0.51, P < 0.05). In normal humans, scopolamine induced a metabolic increase in most brain regions except in the thalamus. Outside this structure, the regional effects of scopolamine were significantlly and negatively correlated (r = -0.58, P < 0.01) between rat and human. These resuts suggest that: (1) cholinergic mechanisms have a similar anatomic distribution in both species, (2) muscarinic receptor-mediated cholinergic effects could predominate outside the thalamus, (3) muscarinic mechanisms are inhibitory in humans but are more complex and possibly excitatory in rats, (4) nicotinic stimulatory effects are found in the thalamus of both species, and (5) physostigmine, but not scopolamine, alters glucose consumption similarly in both species.

Original languageEnglish (US)
Pages (from-to)196-202
Number of pages7
JournalBrain research
Volume635
Issue number1-2
DOIs
StatePublished - Jan 28 1994
Externally publishedYes

Fingerprint

Autoradiography
Positron-Emission Tomography
Cholinergic Agents
Physostigmine
Scopolamine Hydrobromide
Thalamus
Glucose
Brain
Atlases
Muscarinic Receptors
Reproducibility of Results
Energy Metabolism
Rodentia
Alzheimer Disease

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Molecular Biology
  • Clinical Neurology
  • Developmental Biology

Keywords

  • Alzheimer's disease
  • Deoxyglucose
  • Physostigmine
  • Scopolamine

Cite this

@article{77d92185db514c83a6c6a269a04d6afd,
title = "Comparison of cholinergic drug effects on regional brain glucose consumption in rats and humans by means of autoradiography and positron emission tomography",
abstract = "Cholinergic mechanisms have been extensively studied in animals and have been implicated in the pathogenesis of human disorders such as Alzheimer's disease. However, few investigations have directly evaluated the validity of extrapolating the results of animal studies to humans. As a component of a continuing examination of the contribution of cholinergic deficits to the alterations in brain metabolism that occur in Alzeimer's disease, we have compared the effects of scopolamine and physostigmine on regional brain energy metabolism in both rats and humans, using a common region of interest atlas. In Alzheimer's patients and in rodents, physostigmine increased glucose metabolism in several regions (e.g. thalamus) and decreased it in others. Overall, there was a significant positive correlation for the effects of physostigmine in the nineteen brain regions etudied in both species (r = 0.51, P < 0.05). In normal humans, scopolamine induced a metabolic increase in most brain regions except in the thalamus. Outside this structure, the regional effects of scopolamine were significantlly and negatively correlated (r = -0.58, P < 0.01) between rat and human. These resuts suggest that: (1) cholinergic mechanisms have a similar anatomic distribution in both species, (2) muscarinic receptor-mediated cholinergic effects could predominate outside the thalamus, (3) muscarinic mechanisms are inhibitory in humans but are more complex and possibly excitatory in rats, (4) nicotinic stimulatory effects are found in the thalamus of both species, and (5) physostigmine, but not scopolamine, alters glucose consumption similarly in both species.",
keywords = "Alzheimer's disease, Deoxyglucose, Physostigmine, Scopolamine",
author = "J. Blin and Ray, {C. A.} and Piercey, {M. F.} and Bartko, {J. J.} and Mouradian, {M Maral} and Chase, {T. N.}",
year = "1994",
month = "1",
day = "28",
doi = "10.1016/0006-8993(94)91439-7",
language = "English (US)",
volume = "635",
pages = "196--202",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",
number = "1-2",

}

Comparison of cholinergic drug effects on regional brain glucose consumption in rats and humans by means of autoradiography and positron emission tomography. / Blin, J.; Ray, C. A.; Piercey, M. F.; Bartko, J. J.; Mouradian, M Maral; Chase, T. N.

In: Brain research, Vol. 635, No. 1-2, 28.01.1994, p. 196-202.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison of cholinergic drug effects on regional brain glucose consumption in rats and humans by means of autoradiography and positron emission tomography

AU - Blin, J.

AU - Ray, C. A.

AU - Piercey, M. F.

AU - Bartko, J. J.

AU - Mouradian, M Maral

AU - Chase, T. N.

PY - 1994/1/28

Y1 - 1994/1/28

N2 - Cholinergic mechanisms have been extensively studied in animals and have been implicated in the pathogenesis of human disorders such as Alzheimer's disease. However, few investigations have directly evaluated the validity of extrapolating the results of animal studies to humans. As a component of a continuing examination of the contribution of cholinergic deficits to the alterations in brain metabolism that occur in Alzeimer's disease, we have compared the effects of scopolamine and physostigmine on regional brain energy metabolism in both rats and humans, using a common region of interest atlas. In Alzheimer's patients and in rodents, physostigmine increased glucose metabolism in several regions (e.g. thalamus) and decreased it in others. Overall, there was a significant positive correlation for the effects of physostigmine in the nineteen brain regions etudied in both species (r = 0.51, P < 0.05). In normal humans, scopolamine induced a metabolic increase in most brain regions except in the thalamus. Outside this structure, the regional effects of scopolamine were significantlly and negatively correlated (r = -0.58, P < 0.01) between rat and human. These resuts suggest that: (1) cholinergic mechanisms have a similar anatomic distribution in both species, (2) muscarinic receptor-mediated cholinergic effects could predominate outside the thalamus, (3) muscarinic mechanisms are inhibitory in humans but are more complex and possibly excitatory in rats, (4) nicotinic stimulatory effects are found in the thalamus of both species, and (5) physostigmine, but not scopolamine, alters glucose consumption similarly in both species.

AB - Cholinergic mechanisms have been extensively studied in animals and have been implicated in the pathogenesis of human disorders such as Alzheimer's disease. However, few investigations have directly evaluated the validity of extrapolating the results of animal studies to humans. As a component of a continuing examination of the contribution of cholinergic deficits to the alterations in brain metabolism that occur in Alzeimer's disease, we have compared the effects of scopolamine and physostigmine on regional brain energy metabolism in both rats and humans, using a common region of interest atlas. In Alzheimer's patients and in rodents, physostigmine increased glucose metabolism in several regions (e.g. thalamus) and decreased it in others. Overall, there was a significant positive correlation for the effects of physostigmine in the nineteen brain regions etudied in both species (r = 0.51, P < 0.05). In normal humans, scopolamine induced a metabolic increase in most brain regions except in the thalamus. Outside this structure, the regional effects of scopolamine were significantlly and negatively correlated (r = -0.58, P < 0.01) between rat and human. These resuts suggest that: (1) cholinergic mechanisms have a similar anatomic distribution in both species, (2) muscarinic receptor-mediated cholinergic effects could predominate outside the thalamus, (3) muscarinic mechanisms are inhibitory in humans but are more complex and possibly excitatory in rats, (4) nicotinic stimulatory effects are found in the thalamus of both species, and (5) physostigmine, but not scopolamine, alters glucose consumption similarly in both species.

KW - Alzheimer's disease

KW - Deoxyglucose

KW - Physostigmine

KW - Scopolamine

UR - http://www.scopus.com/inward/record.url?scp=0028054743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028054743&partnerID=8YFLogxK

U2 - 10.1016/0006-8993(94)91439-7

DO - 10.1016/0006-8993(94)91439-7

M3 - Article

C2 - 8173955

AN - SCOPUS:0028054743

VL - 635

SP - 196

EP - 202

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 1-2

ER -